CareDx

CareDx, Inc. operates as a transplant diagnostics company, which discovers, develops and commercializes diagnostic solutions. Its products include AlloMap, AlloSure and Laboratory products. The company was founded on December 21, 1998 and is headquartered in Brisbane, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

CareDx reports solid Q4 earnings, eyes profitable growth in 2023

CareDx delivered strong financial results, focusing on profitable growth and strategic initiatives to drive revenue and market leadership.
While facing challenges such as fluctuating transplant volumes and market risks, the company is actively pursuing opportunities for expansion and innovation.
Overall, CareDx's performance, strengths, and proactive approach to challenges and opportunities position it for continued success and growth in the coming year.

CareDx reports Q1 2023 operational success amidst billing challenges

CareDx faced billing challenges impacting Medicare reimbursement but maintained strong operational performance and financial profile. The company is focused on mitigating financial impacts, managing cash flow, and pursuing growth opportunities through new modalities and publications.

CareDx reports Q2 revenue, faces Billing Article impact challenges

CareDx navigated challenges in Q2 2023 with a focus on financial strength, operational excellence, and strategic growth initiatives, despite a decline in Testing Services revenue.
The company's strong cash position, successful strategic executions, and pipeline catalysts position it well for future growth and expansion across Medicare and commercial plans.
While facing uncertainties and cost-saving initiatives, CareDx remains committed to achieving adjusted EBITDA positivity and overcoming challenges to drive long-term value for stakeholders.

CareDx reports solid Q3 earnings, eyes growth through expanded coverage

CareDx's Q3 2023 performance reflects revenue growth and improved EBITDA, driven by key business segments.
While facing challenges like CEO transition and payer coverage, the company is well-positioned for growth opportunities.
Strategic initiatives focusing on expanding coverage and driving testing volume growth indicate a positive outlook for CareDx.

CareDx surpasses revenue targets, eyes growth in transplant services

CareDx delivered strong financial performance in 2023, exceeding revenue guidance and focusing on strategic growth initiatives for 2024.
Despite facing challenges such as ongoing patent litigation and CEO search, the company is well-positioned to drive profitability and expand its offerings.
Opportunities for revenue growth exist in digital solutions, lab products, and transplant services, with potential catalysts for growth on the horizon.
CareDx's advocacy efforts and commercial expansions underscore its commitment to innovation and patient access in the transplant space.

CareDx reports robust Q1 earnings, raises guidance amidst market expansion

CareDx delivered strong financial results, showcasing growth across key business segments and improving EBITDA performance.
The company's focus on innovation, market expansion, and cost management positions it well for future growth and profitability.
With a solid cash position, positive clinical data, and expanded market coverage, CareDx is poised for continued success in the healthcare sector.

CareDx reports strong Q2 earnings, raises FY guidance confidently

CareDx delivered robust financial results in Q2 2024, driven by revenue growth, improved adjusted EBITDA, and successful validation studies for its diagnostic solutions.
The company's raised revenue guidance, expanding payer coverage, and planned Investor Day reflect a positive outlook and strategic focus on long-term growth.
While facing challenges in a competitive landscape, CareDx remains well-positioned to leverage opportunities in transplant diagnostics and healthcare innovation.
Investors can be optimistic about CareDx's performance, innovation pipeline, and strategic initiatives aimed at sustainable growth and market leadership.

CareDx reports robust Q3 earnings, targets $500M revenue by 2027

CareDx delivered strong financial performance in Q3 2024, driven by revenue growth, improved margins, and operational efficiencies.
The company's strategic initiatives to engage transplant centers and expand payer coverage have yielded positive results.
While facing challenges in operational execution and sustaining growth, CareDx remains optimistic about its future prospects and revenue targets.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Los Angeles, California--(Newsfile Corp. - November 8, 2021) -  The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CareDx, Inc ("CareDx" or "the Company") (NASDAQ: CDNA) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. CareDx released its Q3 2021 results on October 28, 2021. The Company...

INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against CareDx, Inc and Encourages Investors with Losses to Contact the Firm

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of CareDx, Inc. (NASDAQ: CDNA) resulting from allegations that CareDx may have issued materially misleading business information to the investing public. SO WHAT: If you purchased CareDx securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rose

EQUITY ALERT: Rosen Law Firm Encourages CareDx, Inc. Investors with Losses in Excess of $100K to Inquire About Class Action Investigation – CDNA

Should you follow the internet's favorite stock picker into this tumbling diagnostics stock?

Why Cathie Wood Is Buying Beaten-Down CareDx

Los Angeles, California--(Newsfile Corp. - November 5, 2021) -  The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CareDx, Inc ("CareDx" or "the Company") (NASDAQ: CDNA) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. CareDx released its Q3 2021 results on October 28, 2021. The Company...

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against CareDx, Inc and Encourages Investors with Losses to Contact the Firm

San Francisco, California--(Newsfile Corp. - November 4, 2021) -  Hagens Berman urges CareDx, Inc. (NASDAQ: CDNA) investors to with significant losses to submit your losses now.Visit: http://www.hbsslaw.com/investor-fraud/CDNA Contact An Attorney Now: CDNA@hbsslaw.com 844-916-0895CareDx, Inc. (CDNA) Investigation: The investigation centers on the accuracy of CareDx's statements concerning its business practices, accounting, and public reporting, particularly pertaining to the company's kidney testing and phlebotomy services.On Oct.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages CareDx (CDNA) Investors with Significant Losses to Contact Firm's Attorneys Now, Firm Investigating Possible Securities Law Violations

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, continues its investigation on behalf of CareDx, Inc. (“CareDx” or the “Company”) (NASDAQ: CDNA) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your CareDx investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact inf

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Its Investigation of CareDx, Inc. (CDNA) on Behalf of Investors

Boston, Massachusetts--(Newsfile Corp. - November 3, 2021) -  Block & Leviton is investigating CarDx, Inc. (NASDAQ: CDNA) for potential securities law violations. Investors who have lost money in their CareDx, Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://www.blockleviton.com/cases/cdna.What is this all about?On October 28, 2021, after the market closed, transplant diagnostics company, CareDx, Inc. released Q3 2021 financial results in which the...

CAREDX INVESTIGATION: Block & Leviton Is Investigating CareDx, Inc. For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)---- $CDNA #investors--The Law Offices of Frank R. Cruz Continues Investigation of CareDx, Inc. (CDNA) on Behalf of Investors

The Law Offices of Frank R. Cruz Continues Investigation of CareDx, Inc. (CDNA) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith continues its investigation on behalf of CareDx, Inc. (“CareDx” or the “Company”) (NASDAQ: CDNA) investors concerning the Company's possible violations of the federal securities laws. On October 28, 2021, after the market closed, CareDx revealed that it had received a civil investigative demand from the U.S. Department of Justice as part of an investigation into the Company's “business practices related to [its] kidney testing and p

INVESTOR ALERT: Law Offices of Howard G. Smith Continues Its Investigation of CareDx, Inc. (CDNA) on Behalf of Investors

SOUTH SAN FRANCISCO, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced that the company has completed its transition from Peter Maag, PhD, to Reginald Seeto, MBBS, as Chief Executive Officer.

CareDx Completes Orderly Management Transition

Boston, Massachusetts--(Newsfile Corp. - November 1, 2021) - The Thornton Law Firm alerts investors that it is investigating CareDx, Inc. (NASDAQ: CDNA) for potential securities violations. Investors who currently own securities of CDNA may contact the Thornton Law Firm's investor protection team by visiting www.tenlaw.com/cases/CareDx for more information. Investors may also email investors@tenlaw.com or call 617-531-3917. FOR MORE INFORMATION: www.tenlaw.com/cases/CareDxOn October 28, 2021, after the market closed, CareDx, Inc. disclosed it is being investigated by...

CDNA Investor Alert: Thornton Law Firm Announces Investigation

LOS ANGELES--(BUSINESS WIRE)---- $CDNA #investors--The Law Offices of Frank R. Cruz Announces Investigation of CareDx, Inc. (CDNA) on Behalf of Investors

The Law Offices of Frank R. Cruz Announces Investigation of CareDx, Inc. (CDNA) on Behalf of Investors

SAN FRANCISCO, Oct. 30, 2021 /PRNewswire/ -- Hagens Berman urges CareDx, Inc. (NASDAQ: CDNA) investors to with significant losses to submit your losses now.  Visit: http://www.hbsslaw.com/investor-fraud/CDNA Contact An Attorney Now: CDNA@hbsslaw.com                                                          844-916-0895 CareDx, Inc. (CDNA) Investigation: The investigation centers on the accuracy of CareDx's statements concerning its business practices, accounting, and public reporting, particularly pertaining to the company's kidney testing and phlebotomy services.

HAGENS BERMAN, NATIONAL TRIAL ATTOREYS, Encourages CareDx (CDNA) Investors with Significant Losses to Contact Firm's Attorneys Now, Firm Investigating Possible Securities Law Violations

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of CareDx, Inc. (“CareDx” or the “Company”) (NASDAQ: CDNA) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your CareDx investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of CareDx, Inc. (CDNA) on Behalf of Investors

OAKLAND, Calif.--(BUSINESS WIRE)---- $CDNA #CDNA--Gibbs Law Group is investigating CareDx Inc. for potential securities law violations.

LOST MONEY IN CAREDX, INC.? Gibbs Law Group Investigates Potential Securities Law Violations

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of CareDx, Inc. (“CareDx” or the “Company”) (NASDAQ: CDNA) investors concerning the Company's possible violations of the federal securities laws. On October 28, 2021, after the market closed, CareDx revealed that it had received a civil investigative demand from the U.S. Department of Justice as part of an investigation into the Company's “business practices related to [its] kidney testing and ph

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of CareDx, Inc. (CDNA) on Behalf of Investors

Boston, Massachusetts--(Newsfile Corp. - October 29, 2021) -  Berman Tabacco, a national law firm representing investors, is investigating potential securities law violations by CareDx, Inc. ("CareDx" or the "Company") (NASDAQ: CDNA), purports to be a "precision medicine company" which "offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients." The Company's headquarters are in South San Francisco, California.On...

CDNA Alert: Berman Tabacco Announces Investigation of CareDx, Inc. in Connection with Government Inquiries

New York, New York--(Newsfile Corp. - October 29, 2021) - Wolf Popper LLP is investigating potential securities fraud claims on behalf of purchasers of CareDx, Inc. (NASDAQ: CDNA) common stock.CareDx develops and commercializes diagnostic solutions for transplant patients. After the market closed on October 28, 2021, CareDx announced strong third quarter 2021 results and increased its 2021 fiscal year revenue guidance. However, CareDx's third quarter 2021 Form 10-Q disclosed that CareDx had received a...

Wolf Popper LLP Announces Investigation on Behalf of Purchasers of CareDx, Inc. (CDNA) Common Stock

CareDx Inc (NASDAQ: CDNA) reported Q3 revenues rose 42% Y/Y to $75.6 million, beating the consensus of $74.05 million.  The increase was driven mainly by a 46% increase in testing service revenues to $66.5 million.

Why Are CareDx Shares Slumping Despite Q3 Earnings Beat?

Third-quarter 2021 results were terrific, but the disclosure of two federal investigations isn't sitting well with investors.

Why CareDx Stock Is Falling Today Despite a Positive Earnings Call

Atlanta, Georgia--(Newsfile Corp. - October 29, 2021) - Holzer & Holzer, LLC is investigating whether CareDx, Inc. ("CareDx" or the "Company") (NASDAQ: CDNA) complied with federal securities laws. On October 28, 2021, in its 10-Q filing, CareDx disclosed that the Department of Justice ("DOJ") issued a civil investigative demand ("CID") "requesting that the Company produce certain documents in connection with a False Claims Act investigation being conducted by the DOJ regarding certain business practices related...

SHAREHOLDER ALERT: Investigation of CareDx, Inc. Announced by Holzer & Holzer, LLC

CareDx, Inc. (CDNA) CEO Reg Seeto on Q3 2021 Results - Earnings Call Transcript

CareDx (CDNA) delivered earnings and revenue surprises of 133.33% and 1.82%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

CareDx (CDNA) Q3 Earnings and Revenues Beat Estimates

SOUTH SAN FRANCISCO, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today reported financial results for the third quarter ended September 30, 2021.

CareDx Reports Third Quarter 2021 Results; Increases Full Year Revenue Guidance

CareDx (CDNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

News for CareDx Stock (CDNA)